Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MassMEDIC lobbies for CDRH funding

This article was originally published in The Gray Sheet

Executive Summary

A March 20 letter to Massachusetts' congressional delegation from the device trade group urges members to work with House Appropriations/Agriculture Subcommittee Ranking Democrat Marcy Kaptur (Ohio) to ensure CDRH receives the additional $22 mil. (plus inflation) in FY 2004 approps needed to keep MDUFMA implementation on track. "This approach ensures that user-fee funds do not displace congressional appropriations, and allows CDRH to upgrade information technology and other infrastructure necessary to carry out a user-fee program and meet the performance goals," MassMEDIC President Tom Sommer writes. CDRH Director David Feigal has indicated the center may use industry fees to compensate for budget shortfalls (1"The Gray Sheet" March 17, 2003, p. 3). The device center must receive $45 mil. (plus inflation) by FY 2005 or the program sunsets...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT018089

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel